Renaissance Technologies LLC Sells 105,556 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)

Renaissance Technologies LLC decreased its holdings in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 60.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 69,100 shares of the company's stock after selling 105,556 shares during the quarter. Renaissance Technologies LLC owned 0.14% of Sight Sciences worth $461,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. American Century Companies Inc. grew its holdings in shares of Sight Sciences by 31.1% in the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company's stock worth $240,000 after acquiring an additional 8,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Sight Sciences by 51.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company's stock worth $141,000 after purchasing an additional 9,106 shares in the last quarter. Steele Capital Management Inc. acquired a new stake in Sight Sciences during the 2nd quarter worth about $67,000. State Board of Administration of Florida Retirement System purchased a new stake in Sight Sciences during the first quarter valued at about $59,000. Finally, Rhumbline Advisers boosted its holdings in shares of Sight Sciences by 40.1% in the second quarter. Rhumbline Advisers now owns 40,811 shares of the company's stock worth $272,000 after buying an additional 11,671 shares during the period. Institutional investors own 55.51% of the company's stock.

Analyst Ratings Changes

SGHT has been the subject of several research analyst reports. Citigroup upped their price target on shares of Sight Sciences from $6.00 to $6.50 and gave the company a "neutral" rating in a research report on Wednesday, July 10th. Lake Street Capital began coverage on Sight Sciences in a report on Wednesday, August 21st. They set a "buy" rating and a $10.00 price target on the stock. Morgan Stanley increased their price objective on Sight Sciences from $5.40 to $6.50 and gave the stock an "equal weight" rating in a research note on Monday, July 15th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research note on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $7.25.

Sight Sciences Stock Up 3.4 %

Shares of NASDAQ:SGHT traded up $0.19 during midday trading on Friday, hitting $5.74. 54,363 shares of the stock were exchanged, compared to its average volume of 194,835. The company has a market capitalization of $285.60 million, a PE ratio of -4.96 and a beta of 2.71. Sight Sciences, Inc. has a 52-week low of $1.04 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. The business's fifty day simple moving average is $6.29 and its two-hundred day simple moving average is $6.25.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. The business had revenue of $21.37 million during the quarter, compared to analyst estimates of $21.32 million. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. During the same quarter in the previous year, the business earned ($0.30) EPS. As a group, research analysts predict that Sight Sciences, Inc. will post -1 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Paul Badawi sold 12,727 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.99, for a total value of $76,234.73. Following the completion of the sale, the chief executive officer now directly owns 5,725,433 shares in the company, valued at approximately $34,295,343.67. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Paul Badawi sold 12,727 shares of Sight Sciences stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.99, for a total value of $76,234.73. Following the transaction, the chief executive officer now owns 5,725,433 shares in the company, valued at $34,295,343.67. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alison Bauerlein sold 10,130 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $6.08, for a total transaction of $61,590.40. Following the sale, the chief financial officer now owns 392,555 shares of the company's stock, valued at $2,386,734.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,305 shares of company stock valued at $207,144. Insiders own 28.90% of the company's stock.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.